ANXA1 and metabolic dysfunction-associated steatotic liver disease: In experimental models of NAFLD/NASH, up-regulation of AnxA1 is already evident in fatty livers and further increases with disease progression specifically involving macrophages containing intracytoplasmatic lipid droplets.